uploads/2018/07/isolated-1188036_1280.png

What Analysts Think of BioLife Solutions Stock

By

Updated

Company overview

BioLife Solutions (BLFS) is focused on bringing to market clinical grade cell and tissue hypothermic storage and cryopreservation freeze media. Its product platforms cater primarily to the biobanking, drug discovery, and regenerative medicine markets. 

In the last five trading sessions, BioLife Solutions stock has risen from a low of $10.90 on June 28 to a high of $17.60 on July 3. The stock closed at $16.70 on July 3.

Article continues below advertisement

Analysts’ recommendations

Of the four analysts covering BioLife Solutions (BLFS) stock in July, one analyst gave the stock a “strong buy” rating, and three analysts gave it a “buy” rating. The mean rating for BioLife Solutions is 1.75 with a target price of $15.75.

Peers’ ratings

Four of the six analysts covering Senseonics Holdings (SENS) in July gave the stock a “strong buy” rating. Two analysts gave it a “buy” rating. The mean rating for SENS stock is 1.33 with a target price of $5.92.

Of the ten analysts covering Abeona Therapeutics (ABEO) in July, two analysts gave the stock a “strong buy” rating. Eight analysts gave the stock a “buy” rating. The mean rating for the stock is 1.8 with a target price of $28.98.

Nine of the 11 analysts covering Abiomed (ABMD) in July gave the stock a “buy” or higher rating, and two analysts gave it a “hold” rating. The mean rating for the stock is 1.73 with a target price of $418.33.

In the next part of this series, we’ll look at BioLife Solutions’ product portfolio.

Advertisement

More From Market Realist